Trial reportEuropean journal of drug metabolism and pharmacokinetics2019
Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin.
Trial report in European journal of drug metabolism and pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07760506 (The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study), which is not on this map. Cited by 126 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study
Who cites it
126 citing papers in PubMed, 1 synthesis or guideline pooled it, 252 citations in OpenAlex.
- Knowledge structure, latent topics, and emerging trends in quercetin-immunity research from 2006 to 2025: a bibliometric and LDA topic-modeling analysis.Frontiers in nutrition · 2026Pooled it
- Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- The effect of quercetin and citrulline on cycling time trial performance.Journal of the International Society of Sports Nutrition · 2024Trial
- Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial.International journal of general medicine · 2021Trial
- Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study.International journal of general medicine · 2021Trial
- Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis.Inflammopharmacology · 2026Article
- Quercetin as a Therapeutic Agent for Oral Cancer: Current Evidence and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- Comparative Effects of Quercetin and its α- and β-D-glucoside Derivatives in LPS-Stimulated C6 Astroglial Cells.Neurochemical research · 2026Article
- Beneficial Role of Quercetin in Prevention and Treatment of Ischemic Stroke: Mechanisms of Action and Administration Strategies.Molecules (Basel, Switzerland) · 2026Review
- Quercetin in COPD: A Multi-Target Approach to Modulate Inflammation, Oxidative Stress, and Epithelial Dysfunction.International journal of molecular sciences · 2026Review
- Preparation of Quercetin-Loaded Lipid Nanoparticle-Embedded Hydrogels and Stability Studies.Molecules (Basel, Switzerland) · 2026Article
- TCM-Derived Small Molecules Targeting Metabolic Vulnerabilities in NSCLC: Ferroptosis-Centered Mechanisms and Emerging Cuproptosis- and Disulfidptosis-Related Vulnerabilities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems.Foods (Basel, Switzerland) · 2026Review
- A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions.Biomedicines · 2026Review
- Sub-acute intraperitoneal quercetin administration causes dose-dependent organ histopathology and oxidative stress in healthy rats: dissociation between serum biomarkers and tissue-level structural injury.Scientific reports · 2026Article
- Targeting the Hedgehog Signaling Pathway in the Retina Using Quercetin-Loaded Lipid Nanoparticles for Myopia Control.Translational vision science & technology · 2026Article
- A Lecithin-Based Delivery Form of Quercetin Promotes Stress Resistance and Longevity inPharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Article
- Self-assembled quercetin-zinc supramolecular nanoparticles exhibit strong antibacterial and anti-biofilm activity against methicillin-resistantFrontiers in microbiology · 2026Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe importance of quercetin and flavonoids in the diet and as food supplements is well known, and literature studies support their potential use to treat several human diseases. Many beneficial properties have been described for quercetin, so much effort has been directed into overcoming the major drawbacks of this natural compound-its poor solubility and low oral absorption. The aims of this study were to compare a new food-grade lecithin-based formulation of quercetin, Quercetin Phytosome
methodsThe solubility of the new formulation was determined by in vitro incubation in simulated gastrointestinal fluids, and quercetin was detected by ultra performance liquid chromatography. A single-dose, randomized, six-sequence/three-period crossover clinical trial (3 × 3 × 3 crossover design) with a balanced carryover effect was conducted in healthy volunteers under fasting conditions. Twelve healthy volunteers of both sexes with an age range of 18-50 years were recruited; one dose of quercetin and two different doses of Quercetin Phytosome were administered orally as film-coated tablets. Pharmacokinetic samples were collected at twelve time points (from 0 h to 24 h) after administration, and quercetin levels were measured by HPLC/MS/MS. Data were analyzed using the Phoenix WinNonlin (v.6.4) software package, and the most significant pharmacokinetic parameters were calculated. Statistical analysis involved performing a two-way ANOVA with repeated measures followed by post hoc analysis (Tukey's test).
resultsSignificant improvements in both in vitro solubility and oral absorption (in terms of both exposure and maximum concentration achieved) by healthy volunteers in a human clinical study were obtained with the Quercetin Phytosome formulation as compared to unformulated quercetin.
conclusionsA more soluble formulation of quercetin based on lecithin, Quercetin Phytosome, has recently been developed, and was found to facilitate the attainment of very high plasma levels of quercetin-up to 20 times more than usually obtained following a dose of quercetin-when the novel formulation was administered orally in human volunteers, and it did not have any notable side effects. These results suggest that Quercetin Phytosome allows the oral administration of quercetin in a safe and bioavailable manner, thus facilitating the effective utilization of this natural compound to treat various human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.